An Open single center arm clinical study of Anti-CD33 CAR-T therapy for relapsed, refractory and high-risk AML
Latest Information Update: 01 Jul 2019
At a glance
- Drugs Anti CD33 chimeric antigen receptor T cell therapy Wuhan Bio Raid Biotechnology (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
Most Recent Events
- 01 Jul 2019 New trial record